# Study of GS-4528 in Adults With Solid Tumors

> **NCT05840224** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 182 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** GS-4528
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT05840224
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-11
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05840224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05840224, "Study of GS-4528 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05840224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*